[Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].

Abstract

Using high performance liquid chromatography and radioimmunoassay we have investigated the stability of prostaglandin (PG) E1 and its metabolite 13,14-dihydro-PGE1 in human plasma as well as the initial metabolism of PGE1 infused intravenously (80 micrograms/patient/hour) in patients with peripheral arterial occlusive disease. 13,14-dihydro-PGE1 degraded like PGE1 in human plasma at 37 degrees C with a half-life of several hours. During infusion of PGE1 higher plasma concentrations of the major metabolite 15-keto-13,14-dihydro-PGE1 and lower plasma levels of PGE1 and 13,14-dihydro-PGE1 were observed. The metabolite 13,14-dihydro-PGE1 is of interest, since in contrast to 15-keto-13,14-dihydro-PGE1 it is biologically active. The biosynthesis of 13,14-dihydro-PGE1 could contribute to the therapeutic efficacy of PGE1 administered intravenously in patients with peripheral arterial occlusive disease.

• Authors: W H Hesse, G Rudofsky, B A Peskar
• Journal: Wiener klinische Wochenschrift (Wien Klin Wochenschr) Vol. 103 Issue 18 Pg. 554-7 ( 1991) ISSN: 0043-5325 [Print] Austria
• Vernacular Title: Metabolismus von intravenös appliziertem Prostaglandin E1 bei Patienten mit peripherer arterieller Verschlusskrankheit.
• PMID: 1750222 (Publication Type: English Abstract, Journal Article)

Chemical References

• 13,14-dihydroprostaglandin E1
• 15-keto-13,14-dihydroprostaglandin E2
• Alprostadil
• Dinoprostone

Topics

• Adult
• Aged
• Aged, 80 and over
• Alprostadil (administration & dosage, analogs & derivatives, pharmacokinetics)
• Arterial Occlusive Diseases (blood, therapy)
• Biotransformation
• Dinoprostone (analogs & derivatives, pharmacokinetics)
• Female
• Humans
• Infusions, Intravenous
• Male
• Middle Aged